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Abstract
Malignancy and many inflammatory diseases have become a major concern for 
mankind over the years. The conventional therapy of these diseases lacks the effective-
ness of the better diagnosis and targeted treatment of these diseases, but nuclear medi-
cine can be regarded as a savior in the current scenario. Over the years, radioactivity of 
radioisotopes has been employed for treatment of many diseases. Nuclear medicines 
came up with radiopharmaceuticals that impart the ability to destroy specific diseased 
cells with high-energy-emitting radionuclides. Moreover, the emergence of theranos-
tics, which is a combination of single drug used both for diagnostic as well as therapeu-
tic purpose, has added a new feather in the field of nuclear medicines for providing a 
specific and personalized treatment to the patient. The current chapter discusses about 
techniques used for imaging of these radionuclides for better therapy and diagnosis of 
the root cause of the concerned disease by positron emission tomography (PET)/CT 
and single photon emission computed tomography (SPECT)/CT as well as the advan-
tages and disadvantages associated with them. It also describes about applications of 
theranostics and nuclear imaging in cancer treatment and their future perspective.
Keywords: radionuclides, nuclear medicines, nuclear imaging, theranostics, 
radiopharmaceuticals
1. Introduction to radioisotopes and radiopharmaceuticals
Scientist has discovered that earth contains many elements with varying configura-
tion. These elements with varying configuration are called isotopes. Isotopes are atoms 
with same atomic number with varying atomic weight. Isotopes can be divided into 
two parts depending on the ability to emit radiation. One that does not emit radiations 
is called stable isotopes and other are called unstable isotopes. Unstable isotopes emit 
radiations to achieve a more stable configuration. These are called as radioisotopes. 
Instability of radioisotopes is due to presence of unstable combination of neutron and 
proton in their atoms and nucleus contains excess of energy. This characteristic of radio-
isotopes can be natural or instability can be created artificially by changing the atoms. 
Naturally radioisotope is uranium-238 and it accounts to 0.7% of total naturally occur-
ring isotopes. Artificial radioisotopes are fluorine and molybdenum which are produced 
artificially by using cyclotrons and nuclear reactors respectively. Presently there are 
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around 3800 radioisotopes out of which 200 radioisotopes are being used. Among the 
isotopes that are used most of them are of artificial origin. Artificial radioisotopes are 
primarily made by two methods as mentioned above i.e. through nuclear reactor and by 
cyclotron. By nuclear reactor neutrons are introduced into the nucleus of atom whereas 
in case of cyclotron proton are introduced. To become stable radioisotopes emits alpha 
or beta particle along with electromagnetic radiation of gamma rays. This phenomenon 
is called as radioactive decay. These radioisotopes have variety of uses, when they are 
used in the field of pharmaceuticals they are termed as radiopharmaceuticals.
1.1 Radiopharmaceuticals
These are radioactive medicines that can be given by oral, intravenous or inter-
stitial route to treat or diagnose malignancy. Administration of these drugs is done 
in the presence of specialist called radio pharmacist. These radioactive medicines 
have the ability to destroy cancerous cell by emitting radiation when it reaches its 
target cell. Radiopharmaceuticals for treatment and diagnosis of cancers associated 
with thyroid, brain, bones or lymphoma already been discovered.
In addition to treatment radiopharmaceuticals are also used for the purpose 
of diagnosis. The drugs used for diagnosis are called as tracers. The radiation of 
diagnostic radiopharmaceuticals is smaller as compared to radiation emitted by 
radiopharmaceuticals used for treatment. Radiopharmaceuticals are either single 
isotopes or sometimes the isotopes are combined with a kit [1]. The kit is prepackag-
ing of ingredients which are sterile and are meant for preparation of radiopharma-
ceuticals. They are combination of substances such as antioxidant, buffer, reductant 
and ligands that are when combined with the radioisotopes produces the resultant 
product. Kits are very beneficial as they are not in contact with the outer environ-
ment so there is no chance of any contamination [2].
1.2 Technetium 99m
The isotope that is used for the purpose of labeling of kits used for diagnosis is 
technetium 99m abbreviated as 99mTc (Figure 1). It radiates only gamma radiation 
that is compatible with gamma camera. 99mTc also has the property of binding 
with the tracers. Advantage of technetium is that it has smaller biological half-life 
and better renal clearance for the unabsorbed radiopharmaceuticals that helps in 
getting a better quality of image from the absorbed ones. The dose of technetium 
depends on the kit, the organ on which it has to be used for imaging and on the test 
to be performed [3]. Determination of dose for children is very crucial as the cells 
Figure 1. 
Chemical structure of technetium 99m.
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are in dividing states so sensitivity towards radiation can be higher, organ size body 
ratio also varies to greater extent in comparison with adult. So in case of children a 
balanced level of administration is required [4].
Different kit labeled with 99mTc used for imaging of different organs is men-
tioned below.
1.2.1 Bone
For detection of the areas that are metabolizing the bones kits with bisphos-
phonates are used. Scan of bone is done by injecting radiopharmaceuticals into the 
peripheral vein of patient and then after 3 h imaging is done so that within the three 
hours the bisphosphonates will get incorporated into the osteoblast cells.
1.2.2 Kidney
For the imaging of kidney, there are three radiopharmaceuticals, namely
i. Radiolabelled mercaptoacetyltriglycine (Mag-3; mertiatide)
ii. Radiolabelled diethylenetriaminepentaacetic acid (DTPA; pentetate)
iii. Radiolabelled dimercaptosuccinic acid (DMSA; succimer
Mag-3; mertiatide is used for the purpose of determining the blood flow to the 
kidney and for graphically presenting the renal function. Mag-3 has a clearance 
of 94% after 3 h that helps in getting better quality of image and the exposure of 
patient to the radiation is also lower. DTPA; pentetate is used to determining rate 
of glomerular filtration during chemotherapy of kidney. Lastly DMSA; succimer is 
used a tool for studying morphology of renal cortex and ectopic kidney.
1.2.3 Brain
Kit used for the check the blood flow within the brain after conditions like 
epilepsy, migraine or Alzheimer’s disease or stroke of brain contains 99mTc-labeled 
exametazime. This is product of lipophilic origin without any charge on it and it 
penetrates better through blood brain barrier. It takes around one minute after 
injection for it to reach brain and up to 7% reaches the brain.
1.2.4 Heart
For cardiac imaging, two 99mTc-labeled are tetrofosmin and sestamibi which 
are employed to ascertain the degree to which myocardial infarction is severe and 
also help to point out the regions of cardiac ischemia. Images are collected at the 
state of rest and after stressed activity of cardiac cells. This injection are admin-
istered when patient must have consumed any kind of fatty meal. This helps in 
hepatobiliary clearance of administered radiopharmaceuticals thus aid in getting 
better image. But it should not be administered when patients has consumed some 
drugs such as nitrates or calcium channel blockers.
1.2.5 Lungs
In case of lungs scan it is used for the purpose of diagnosis of any kind of 
embolism in pulmonary tract. Lung scan be of two types perfusion scan or 
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ventilation scan. First, one 99mTc-labeled macroaggregated albumin is injected in 
the peripheral vein, which is then carried to the pulmonary artery system. It does 
not get absorbed rather it gets distributed evenly in the capillary bed and helps 
in diagnosis. Where blood flow is good there will be larger number of particles 
giving out radiation, whereas where there will less perfusion then less particles 
will be seen.
In case of ventilation scan, patient is made to inhale radioactive substance such 
as krypton or 99mTc-labeled DTPA aerosol. Image is obtained where air is seen 
circulating in lungs [5].
1.3 Adverse reactions
The most common adverse reaction associated with radiopharmaceuticals is 
sweating, nausea, dry mouth and rashes.
2.  Recent approaches of injectable radiopharmaceuticals as nuclear 
medicine for imaging and therapy
The aim of this chapter is to explain about advancements the injectable of 
biomaterials or radiopharmaceuticals origin used in molecular imaging, therapy 
and clinical diagnosis. On the basis of intrinsic radiation form, radioisotopes can be 
divided into following type namely gamma (γ) ray emitters, beta (positron β+ or 
electron β−) particles emitters and alpha (α) particles emitters or their combina-
tions. In clinical practice and pre-clinical animal studies, mostly used radionuclides 
are gamma ray emitters like Technetium-99m (99mTc), Iodine-123 (123I) and 
Galium-67 (67Ga), Positron-emitting radionuclides namely Fluorine-18 (18F), 
Oxygen-15 (15O), Carbon-11 (11C) and Zirconium 89 (89Zr). Some β-emitters are 
Rhenium-186/Rhenium-188 (186Re/188Re), Strontium-89 (89Sr), and Yttrium-90 
(90Y). Examples of therapeutic α-emitters are Actinium-225 (225Ac), Bismuth-213 
(213Bi) and Astatine-211 (211At) [6]. The injected radiopharmaceuticals can be in 
simple ionic form or in carrier complex form. Carrier complex has better targeting 
ability for certain tissues and cells and pathways of disease. These are some radio-
isotopes used for imaging are as follows (Table 1):
Organ Isotope used/activity
Brain In-113m/7–10 mCi
Kidney Hg-197/150 mCi
Lungs Tc-99/1 mCi
I-131/0.15–0.3 mCi
In-113/1 mCi
Spleen Cr-51/0.3 mCi
Bone Sr-85/0.1 mCi
Sr-87/1 mCi
F-18/1 mCi
Pancreas Se-75/0.2 mCi
Placenta Cr-51/0.05 mCi
Tc-99/0.5–1 mCi
Table 1. 
Radioisotope imaging [7].
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In case of imaging, the major focus was development of 11C, 18F or 68Ga 
radiopharmaceuticals to be used in positron emission tomography (PET) and 
99mTc-labeled agents for the used in single-photon emission computed tomography 
(SPECT) [8]. The merits associated with nuclear medicine are many such as it is 
noninvasive, it gives better in identifying exact region of tumor and beneficial for 
diagnosis of challenging diseases [9, 10]. In addition to this there is better quantita-
tive analysis which is achieved with a numerous tools available. For example stan-
dard uptake values (SUVs) are taken in PET and in case of SPECT it is compared 
in vivo distribution of the injected materials [11]. There are some common nuclides 
mentioned in Table 2 which are used in radiation therapy are:
This content focuses on the developments in field of imaging technology in 
relevance to imaging of radionuclide therapy.
2.1 SPECT and scintigraphy
This type of decay of radionuclides determines about the modality for imaging. 
Planar scintigraphy or SPECT is used for imaging of 177Lu, 90Y, and 131I-which are 
used for radionuclide therapy. These emit γ-photons (or bremsstrahlung photons), 
which can be imaged by a γ-camera.
2.1.1 Current status
SPECT/CT systems which are used nowadays are used for both planar and tomo-
graphic imaging. Planar imaging is for acquiring whole-body images in when there 
is limitation of time. SPECT is meant for acquiring 3-dimensional data of structures 
which would otherwise overlap on each another on planar images.
Quantitative analysis of SPECT images is determined by converting the acquired 
counts in terms of distribution of absorbed dose (in Gy), which is beneficial for 
planning and dosimetry of therapy involving radionuclide. In clinical practice scat-
ter correction is also implemented and is generally performed employing the triple-
energy window method [13]. Quality of image can be enhanced by using resolution 
recovery. It is performed by characterizing the shape of the point-spread function 
accurately, that depends its distance from the camera and there is rotational varia-
tion due to the hexagonal pattern of the collimator septa. Reconstruction algorithm 
can be incorporated with point-spread function model subsequently [14].
Effects like scatter, blurring and attenuation which degrades image can be cor-
rected to some extent, Although SPECT images can be degraded by partial-volume 
effects and quantification errors.
2.2 PET
18F-FDG PET is used for many PET studies that are in the field of clinical 
practice and is employed for staging and follow-up post radionuclide therapy. 
Nuclide Radiation Half-Life Treatment
32P Β 14.3 d Leukemia therapy
60Co β, γ 5.3 yr External cancer therapy
123I Γ 13.3 yr Thyroid therapy
131Cs Γ 9.7 days Prostate cancer therapy
192Ir β, γ 74 d Coronary disease
Table 2. 
Radiation therapy [12].
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However, PET has application in planning of treatment, dosimetry, and assessment 
of treatment after radionuclide therapies.
2.2.1 Current status
Similar to SPECT quantitative PET is also used for correction techniques. 
Correction of attenuation for PET can be done through determination of the 
sonogram associated with attenuation correction, which works on the basis of co-
registered CT data. Scatter correction is often done with single-scatter simulation 
method in clinical practice [15]. Correction for random counts is often done using 
delayed-event subtraction [16].
The difference in time between annihilation photons gives information regard-
ing location of the annihilation and also about the line of response. Now time-of-
flight information in the reconstruction at the time of back projection step enhances 
image quality. The availability of time-of-flight estimation has opened the opportu-
nities for low positron abundance imaging isotopes like 90Y.
As intrinsic resolution of PET detectors are not freely available, so shape of the 
point-spread function is used to improve the quality of images by incorporating it 
during reconstruction method. This is called as resolution recovery.
When there are high count rate radiation detection systems does not work prop-
erly due to dead-time effect caused by pulse pile-up. Because of these Dead-time 
losses are corrected regularly.
2.2.2 Advances
There are better quality of PET images with enhanced resolutions and sensitivity 
due to regular improvement in the instrument which provides precise determina-
tion of the SUV [17].
2.3 PET/MRI
The advantages of PET/MRI over PET/CT are higher soft-tissue contrast that 
is essential for planning of treatment, dosimetry, and assessment post radionu-
clide therapies. Additionally, for accurate dosimetry it is beneficial as it provides 
the simultaneous coregisteration of MR images. Also, MRI can be employed for 
determining the tolerable dose with least organ damaging activity of radionuclide. 
Along with it anatomic and molecular images acquisition provides better motion 
correction.
Integrating of PET and MRI modalities is challenging as there will be interfer-
ence between both the modalities. For instance, photomultiplier tubes that are 
present in PET detectors malfunction in magnetic fields exerted by MRI. In addition 
to this, PET module affects the radiofrequency signal associated with MRI [18]. 
Due to this, the first generation of PET/MRI systems modalities were separated. 
Integration of PET detectors and MR scanner has been done to obtain PET and MR 
images simultaneously. Detector systems is avalanche photodiodes types or SiPMs 
types which are not sensitive to magnetic field. The simultaneous measurement 
provides better 4-dimensional acquisitions because of spatial agreement of PET and 
MRI data.
Disadvantages associated with PET/MRI are high costs and the ferromagnetic 
metallic implants which are used is contradictory to MRI. In addition to this it’s 
challenging to correct attenuation of PET/MRI. For dosimetry it is essential to have 
accurate attenuation correction. As CT images are electron-density images and 
MR images are proton density image, CT image are better suited for attenuation 
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correction. But MR images can be used for attenuation correction by using tech-
niques such as segmentation-based or template- or atlas-based which derives 
electron density information from MR images [19]. Alternatively, estimation of the 
attenuation maps can be done by employing algorithms which uses the time-of-
flight emission or transmission data [20].
2.4 Future perspectives
2.4.1 Simultaneous X-ray and nuclear imaging
Till today there are no real-time hybrid imaging modalities that can merge 
nuclear and anatomic for interventional purposes. Fluoroscopic imaging in combi-
nation with real-time nuclear imaging gives physicians with valuable information 
during procedures like as 90Y liver radio embolization by image distribution of the 
radionuclide in association with the anatomy and the interventional instruments 
that enhances therapeutic efficiency. Image of same field can be seen by arranging 
X-ray tube, an X-ray detector, and a γ-camera in a single line [21].
3.  Different types and applications of radioisotopes for imaging and 
therapy
S. no Radioisotopes Uses
1. Calcium-47 Important aid to biomedical researchers studying cellular functions and 
bone formation in mammals
2. Caesuim-137 Used to treat cancerous tumors and to measure correct dosages of 
radioactive pharmaceuticals
3. Chromium-51 Used in research in red blood cells survival studies
4. Cobalt-57 Used as a tracer to diagnose pernicious anemia
5. Cobalt-60 Used to sterilize surgical instruments and used in cancer treatment, food 
irradiation and radiography
6. Copper-67 When injected to monoclonal antibodies into a cancer patient, helps the 
antibodies bind to and destroy the tumor
7. Gallium-67 Used in medical diagnosis
8. Iodine-123 Widely used to diagnose thyroid disorders and other metabolic disorders 
including brain functions
9. Iodine-125 Major diagnostic tool used in clinical test and to diagnose thyroid 
disorders. Also used in biomedical research
10. Iodine-129 Used to check some radioactivity counters in in-vitro diagnostic testing 
laboratories
11. Iodine-131 Used to treat thyroid disorders (Graves’ disease)
12. Iridium-192 In brachytherapy/tumor irradiation
13. Phosphorous-32 and 
Phosphorous-33
Used in molecular biology and genetics research
14. Technetium-99m Most widely used radioactive pharmaceutical for diagnostic studies in 
nuclear medicine. Different chemical forms are used for brain, bone, 
liver, spleen and kidney imaging
15. Uranium-234 Used in dental fixtures like crowns and dentures to provide a natural 
color and brightness
16. Xenon-133 Used in nuclear medicine for lung ventilation and blood flow studies
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3.1 Applications
Applications of different radioactive isotopes in nuclear medicine are [22]:
• Cobalt-60 is used in radiation therapy for prevention of cancer.
• Iodine-131 has been used for locating brain tumors, monitor activity of 
cardiac, liver and thyroid cells.
• Carbon-14 used for determining metabolic changes happening in patients of 
diabetes, gout and anemia.
• Carbon-11 is used to monitor organs during PET scan by tagging it into glucose.
• Thallium-201 has been in use for determining damage in heart tissue, detection 
of tumors.
• Technetium-99m act as radiotracer in medical diagnostics for obtaining the 
image of organs and study of blood flow. It also crucial for locating brain 
tumors and damaged heart cells [23].
4. Advantages and disadvantages of injectable radiopharmaceuticals
4.1 Properties of all radiopharmaceutical injectable
1. It should be sterile and free from Pyrogens. Sterility means absence of any 
living things even the spores or any related substances that can develop into 
something living. Culturing samples with special growth media is most com-
mon way to perform the assessment of sterility. Pyrogens are endotoxins that 
have the ability to cause pyrexia. They cannot be destroyed by autoclave and 
cannot be filtered. Testing for Pyrogens can be tested by using the rabbit test or 
the Limulus amebocyte lysate (LAL) test.
2. The isotonicity of injectable drug should be equal to 0.9% NaCl solution, and 
the pH should be 7.5.
3. In case of radioactive substance dose calibration should be done and it should 
be within ±10% of the prescribed dose. This calibration provides assurance 
that dose is as low as possible and it gives high quality image.
4.1.1 Advantages
• It is used for diagnosis and treatment of patients.
• It is commonly used to cure to cancers and can treat many other sites of disease.
• Treats tumor such as bone metastasis.
• Provide faster onset of relief from pain.
• Single dose is effective for some patients.
• Tests of nuclear medicine can be done on children.
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• Nuclear medicine procedure less costly and painless.
• Nuclear medicine procedures are safe with no side effects [24].
4.1.2 Disadvantages
• Some allergic reactions can be seen.
• Risk of radiation is associated.
• Myelosuppression may occur before chemotherapy.
• Prolonged in convenience and discomfort can be experienced by patients due 
to administration of multiple fraction.
• Nuclear medicine tests cannot use for pregnant women because of potential 
risk to unborn babies.
5. Theranostics
Theranostics is a combination of two words Therapeutics and diagnostics. This is 
an emerging field of medicine where drugs and/or techniques are used in combination 
for treatment as well as treatment. It’s a game changer as it provides diagnosis as well 
as therapy in single combination. It is economical as well as less time consuming. It 
uses PET scan to target tumor receptors which are present in tumor cell. If it is found 
in the cells radioactive drug is used to treat it. There are not much clinical trials found 
related to use of application of theranostics in prostate cancer by Australian Medicines 
Regulator—The Therapeutic Goods Administration (TGA) [25] (Figure 2).
5.1 Theranostics: Nuclear Medicine Imaging
The Nuclear Medicine Imaging approach is revolutionized by use theranostics 
[targeted therapeutic (Rx) + companion diagnostic (DX)] to establish tools for 
specific molecular targeting. It provides personalized treatment plan for the patient 
by targeting specific targets. Various department of nuclear science can utilize 
theranostic agents [26].
Figure 2. 
Theranostics working on tumor cell.
Medical Isotopes
10
5.2 Therapeutic bullets
Theranostics takes advantage of biological pathways specific to any system of 
human body to acquire diagnostic images. These images enhances the probability 
that the targeted therapeutic dosing of radiation that will only target disease part 
sparing the healthy one.
5.3 Nuclear Medicine Imaging
In past 100 years a similar kind of model for neuroendocrine tumors has been 
developed that has used radionuclide gallium-68. This PET radiotracer has been 
chelated to DOTA-octreotate and used for diagnosis of tumor with higher sensitiv-
ity compared to Indium-111 octreotide imaging.
The disease of patients can be determined by using the gallium-68 DOTA-TATE 
for targeting the somatostatin receptor volume and having image using hybrid scan-
ner like PET-CT (Positron Emission Tomography-Computer Tomography). Lutetium 
Octreotate Therapy is a radiopharmaceuticals which emits beta radiation is available 
in 5 medical centers in north America and European medical centers [27].
Some of the milestones in the field of theranostics becoming personalized 
medicine are as follows:
• Lutetium PSMA therapy for metastatic or treatment-resistant prostate cancer
• Yttrium-90 SIRT therapy for liver cancer
• Iodine-131 therapy for thyrotoxicosis and thyroid cancer
• Radium-223 therapy for metastatic prostate cancer in bones
• Yttrium-90 radiosynovectomy therapy for inflammatory synovitis of joints
Theranostics targeted therapy is difficult in case of cancer treatment due to het-
erogeneity of cancer cells. Ibritumomab a monoclonal antibody detects B-cells and 
produces the beta/alpha-emitting radiometal for destroying the lymphoma. SPECT 
imaging confirms distribution of antibody in the body. The indium-111 combined 
with radionuclide yttrium-90 transports beta particles for killing the B-cells [28] 
(Figure 3).
Figure 3. 
Theranostics in cancer targeting and treatment.
11
Theranostics: New Era in Nuclear Medicine and Radiopharmaceuticals
DOI: http://dx.doi.org/10.5772/intechopen.91868
5.4 Theranostics: Zevalin therapy
Zevalin therapy is used for determining the indications for relapsed or refractory, 
low-grade or follicular, B-cell non-Hodgkin’s lymphoma. Zevalin is FDA approved for 
the treatment of relapsed or refractory low-grade follicular. In the year 2008 Zevalin 
was approved as the first-line drug for follicular lymphoma in the European Union.
5.4.1 Characteristics
5.4.1.1 Diagnostic component
The diagnostic component contains radiotracer, a contrast agent molecule, and 
a particulate system with either inherent physical property like optical, magnetic 
property or an acquired physical property such as, contrast enhanced ultrasound 
property or combinations of both. Combination systems exhibits dual functions 
like oximetry and detection in cellular and molecular imaging [29].
5.4.1.2 Therapeutic component
The therapeutic component includes drug molecule that is associated with 
diagnostic component or carrier system. Examples of the former are radiotracer-
labeled non-peptide like gallium-68-labeled bisphosphonates for osteoblastic bone 
metastases and peptide-based molecules such as gallium-68-labeled somatostatin 
analogs for somatostatin receptor which targets neuroendocrine tumors. Examples 
of therapeutic components associated with a carrier system are where integrated 
entities are attaches to macromolecular carrier covalently. In addition to this, drug 
molecules co-encapsulation is done with diagnostic components such as chelated 
radiotracers and gadolinium (III), quantum dots, gold nanoparticle into particulate 
carrier systems namely polymeric nanospheres, liposomes, polymersomes, and 
mesoporous silica nanoparticles.
5.5 The application of theranostics in cancer
Cancer is a serious condition of heterogeneous group of diseases where there 
is uncontrolled and rapid cell growth. This is because of changes at genetic and/or 
epigenetic level in patient’s body. Current treatment for cancer is chemotherapy, 
radiotherapy, immunotherapy and surgery.
Chemotherapy is not that much useful as a very low level of concentration 
of drug reaches the tumor. Moreover there is chances development of resistance 
during treatment and associated side effects. For example, chemotherapeutic agents 
known as taxanes have emerged as one of the most powerful classes of compounds 
to combat cancer, exhibiting a wide range of activity. The tubulin/microtubule 
complex has been proven to be a clinically useful antitumor target. The examples 
of chemotherapeutics that act via perturbation of tubulin polymerization include 
paclitaxel (Taxol®), docetaxel (Taxotere®), vinblastine, and discodermolide. First, 
docetaxel is a semi-synthetic derivative of paclitaxel. Next, vinblastine, unlike the 
other three compounds that all stabilize microtubules, aggregates tubulin and leads 
to microtubule depolymerisation. Randomized clinical trials evaluating docetaxel 
and paclitaxel in a first-line treatment setting for metastatic breast, lung, ovarian, 
and digestive cancers, as well as in the adjuvant setting for breast cancer, have 
confirmed that taxanes are leading contributors to the armamentarium of cancer 
treatments. Paclitaxel is used as a first-line chemotherapy treatment for NSCLC, but 
patients’ acquired resistance becomes a critical problem.
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Here nanomedicine is better as it allows molecular targeting to get higher con-
centrations of drug molecules at targeted site. Studies have been to make sure that 
required amount of drug reaches the site actively or passively which ensures better 
therapeutic index.
Few examples of nanomedicine in this context are polymeric micelles, polymer-
drug conjugates and liposomes. Whereas traditional small molecular drugs n get 
eliminated from bloodstream quickly but nanomedicine possess longer half-lives.
Furthermore there is enhanced bioavailability and augmented tumor deliv-
ery. In addition to it integration of imaging and nanomedicine helps as diag-
nostic arm of theranostics. The advantages of using such strategy are immense, 
that will assist in management of oncogenic conditions with the help of ther-
anostics [30].
Applications of theranostics in medicine include:
• It is a noninvasive molecular imaging method to evaluate of disease 
heterogeneity.
• Gives better idea about biodistribution and about accumulation of drug at 
target-site.
• Better understanding of process of local drug release.
• Facilitation of drug release (through application of stimuli-responsive 
theranostics).
• Prediction of drug responses and associated adverse effects with personalized 
therapies [31].
6. Health and safety
Radiopharmaceuticals are as safe as other medicine and before use they are 
tested carefully.
• The quantity of the pharmaceutical part of the radiopharmaceutical is very 
small, generally 1/10th of a millionth of an ounce. The risk of a reaction is 2–3 
incidents per 100,000 injections, over 50% of which are rashes as compared to 
2000–3000 per 100,000 injections of X-ray contrast media.
• For childrens most radiopharmaceuticals, the amount of radiation used for a 
diagnostic test is very low and considered safe [32].
• Radiopharmaceuticals usually are not recommended for use during pregnancy. 
This is to avoid exposing the fetus to radiation. His is specially important with 
radiopharmaceuticals that contain radioactive iodine, which can go to the 
baby’s thyroid gland and in high enough amounts may cause thyroid damage.
• Although exposure to the radioactivity in very large doses can be harmful 
the radioactivity in radiopharmaceuticals is carefully selected by the nuclear 
medicine physician to be safe.
• If anybody will be receiving albumin in the form of radioiodinated albumin, 
technetium Tc 99m albumin aggregated, technetium Tc 99m albumin colloid, 
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or technetium Tc 99m albumin for test, Consult doctor if have ever had any 
unusual or allergic reaction to products containing human serum albumin [33].
• Side effects: when radiopharmaceuticals are used in very small doses to study 
an organ of the body, side effects are rare and usually involve an allergic reac-
tion. These effects may occur almost immediately or a few minutes after the 
radiopharmaceutical is given.
7. Conclusion
In recent past radiopharmaceuticals made steady progress towards nuclear imaging 
and therapy. The benefit of molecular imaging and therapy can obtain when required 
amount of diagnostic probes reaches the targeted site. Effort have been taken in 
enhancing specificity of targeted radiotracers in both pre-clinical research and clinical 
trials. In recent discussions the advancement in the said field has been discussed taking 
into account multi-modal molecular imaging probes for sentinel lymph node mapping 
and image-guided surgery, radiotracers for targeted imaging of cancer and neurode-
generative diseases, along with probes for monitoring therapy responses. For better 
diagnosis and therapy design of radiopharmaceuticals as well as route of administra-
tion plays a major role. At last dose of radioactive medicine should be set with caution 
to prevent over exposure of patient, the principle of ‘As Low as Reasonably Achievable’ 
(ALARA) used for protection of employee as well as general public. The knowledge 
about medical physics is essential because of interactions between ionizing radiation 
and biological tissues. According to author we can be optimistic for the future growth 
of radiopharmaceuticals. This trend can be seen in recent future with the help of 
thriving research and fast translations into clinic. The high cost, demanding hardware 
requirements and specialized personnel training are major factors that may confine 
the development of radiopharmaceuticals. However, the huge needs for nuclear 
medicine from the public and the benefits to patient care far outweigh the risks.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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